Compare GDC & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDC | CDIO |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 6.1M |
| IPO Year | N/A | 2021 |
| Metric | GDC | CDIO |
|---|---|---|
| Price | $1.45 | $1.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 30.6K |
| Earning Date | 04-10-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,825.00 |
| Revenue This Year | N/A | $171,906.75 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.47 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.01 | $0.97 |
| 52 Week High | $8.18 | $7.91 |
| Indicator | GDC | CDIO |
|---|---|---|
| Relative Strength Index (RSI) | 50.78 | 48.54 |
| Support Level | $1.32 | $1.71 |
| Resistance Level | $2.07 | $2.08 |
| Average True Range (ATR) | 0.18 | 0.14 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 28.55 | 29.12 |
GD Culture Group Ltd operates and manages its business as a single segment and has one operating and reportable segment, the Virtual Content Production. The company has relentlessly been focusing on serving its customers and creating value for them through the continual innovation and optimization of its products and services. For the AI-driven digital human creation and customization sector, the Company uses AI algorithms and software to generate realistic 3D or 2D digital human models. AI algorithms and machine learning models are used to simulate human characteristics, such as facial expressions, body movements, and even speech patterns.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.